DOCSLIB.ORG

HUTCHMED (China) Limited Supplemental and Updated Disclosures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HUTCHMED (China) Limited Supplemental and Updated Disclosures HUTCHMED (China) Limited Supplemental and Updated Disclosures We recently filed an application (the “Listing Application”) with The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) in connection with a proposed listing (the “Listing”) of our ordinary shares, par value US$0.10 per share (“Shares”), on the Main Board of the Stock Exchange. The Listing Application contains supplemental and additional descriptions of certain aspects of our business and financial information as required by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as well as updated disclosure of certain information previously disclosed in our annual report on Form 20-F for the year ended December 31, 2020 filed on March 4, 2021 (the “2020 Annual Report”). This exhibit sets forth such new, supplemental and updated information and disclosures as described below. The disclosure herein supplements and should be read in conjunction with the disclosure in our 2020 Annual Report and other disclosures furnished on Form 6-K. There is no assurance as to if or when such Listing will take place. This communication is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any offer, solicitation or sale of our securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. -1- FORWARD LOOKING STATEMENTS This Exhibit contains forward-looking statements that involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “positioned,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions, are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. As a result, any or all of our forward-looking statements in this Exhibit may turn out to be inaccurate. We have included important factors in the cautionary statements included in this Exhibit and in the 2020 Annual Report, particularly in the section of the 2020 Annual Report titled “Risk Factors”, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Moreover, we operate in a highly competitive and rapidly changing environment in which new risks often emerge. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward- looking statements we may make. The forward-looking statements contained herein are made as of the date of the filing of this Exhibit, and we do not assume any obligation to update any forward-looking statements except as required by applicable law. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statements are made or to reflect the occurrence of unanticipated events. Youshould read this Exhibit completely in conjunction with our annual reports on Form 20-F and other documents filed with or furnished to the SEC and with the understanding that our actual future results may be materially different from what we expect. -2- TABLE OF CONTENTS Recent Developments ....................................................... 4 Information About the Listing ................................................ 11 Risk Factors ............................................................. 13 Industry Overview ......................................................... 20 Business ................................................................. 78 Financial Information ...................................................... 161 -3- RECENT DEVELOPMENTS The following sets forth updated information subsequent to the filing of our 2020 Annual Report. For our unaudited consolidated financial statements as of March 31, 2021 and for the three months ended March 31, 2020 and 2021, please refer to Exhibit 99.1, titled “Unaudited First Quarter 2021 Financial Information”, of our report on Form 6-K to be furnished to the SEC and the related disclosures contained herein and therein. SUMMARY OF FIRST QUARTER 2021 HIGHLIGHTS Cash and cash equivalents and short-term investments were US$396.1 million as of March 31, 2021 compared to US$435.2 million as of December 31, 2020. Revenues increased by 58.1% to US$81.6 million for the three months ended March 31, 2021 from US$51.6 million for the three months ended March 31, 2020. • Oncology/Immunology revenues increased by 227.3% to US$21.7 million for the three months ended March 31, 2021 from US$6.6 million for the three months ended March 31, 2020. • Accelerating Sales Growth of Elunate – Sales of Elunate generated revenues of US$13.4 million for the three months ended March 31, 2021 compared to US$2.9 million for the three months ended March 31, 2020. In-market sales of Elunate were US$20.2 million for the three months ended March 31, 2021 compared to US$7.3 million for the three months ended March 31, 2020, as provided by Eli Lilly. • Launch of Sulanda – We commercially launched Sulanda as a treatment for patients with advanced non-pancreatic NET in China in mid-January 2021 within three weeks of approval from China’s National Medical Products Administration (the “NMPA”). We had revenues of US$5.5 million from sales of Sulanda for the three months ended March 31, 2021. • Other Ventures revenues increased by 33.2% to US$59.9 million for the three months ended March 31, 2021 from US$45.0 million for the three months ended March 31, 2020. Research and development expenses incurred by Oncology/Immunology increased by 87.0% to US$57.1 million for the three months ended March 31, 2021 from US$30.5 million for the three months ended March 31, 2020, primarily due to a significant expansion of clinical activities in the United States and rapid organizational growth to support such expansion. In particular, this increase was attributable to the expansion of the fruquintinib, surufatinib, HMPL-689 and HMPL-306 development programs. Our international clinical and regulatory operations in the United States and Europe incurred research and development expenses of US$30.6 million for the three months ended March 31, 2021 compared to US$8.0 million for the three months ended March 31, 2020. We expect to incur significant expenses, particularly research and development expenses, for the foreseeable future as we expand our development of, and seek regulatory approvals for, our drug candidates. Net loss attributable to our Company was US$41.1 million for the three months ended March 31, 2021 compared to US$16.1 million for the three months ended March 31, 2020. Net loss attributable to our Company was US$0.06 per ordinary share for the three months ended March 31, 2021 compared to US$0.02 per ordinary share for the three months ended March 31, 2020. BUSINESS UPDATES Recent Disposal On March 24, 2021, we entered into a sale and purchase agreement with GL Mountrose Investment Two Limited, a company controlled and managed by GL Capital Group, to sell our entire investment in -4- Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, our non-consolidated joint venture (“Hutchison Baiyunshan”). GL Capital Group is an investment firm that focuses on buyout and growth opportunities in China’s healthcare industry and is an independent third party which has a minority interest in the Company and is not a connected person of the Company. The disposal is subject to regulatory approval in China and is expected to be completed in the second half of 2021. The aggregate amounts to be received attributable to the Company are approximately US$169 million, of which approximately US$127 million is related to our shareholding in Hutchison Baiyunshan and approximately US$42 million is related to distributions of the land compensation and the prior year’s undistributed profits. A deposit of approximately US$15.9 million paid upon signing of the agreement will be credited against the proceeds due on completion of the disposal. Following the completion of the disposal, the Group will cease equity accounting of the financial results of Hutchison Baiyunshan, and will derecognize the carrying value of the Company’s investment in Hutchison Baiyunshan and recognize a disposal gain attributable to the Company estimated at approximately US$80-90 million, net of taxes. The Group will exit from the over-the-counter drug arena upon the disposal. As our focus is the discovery and development of novel therapies in oncology and immunology, the sale of our interest in Hutchison Baiyunshan will allow us to focus resources on our primary aim of accelerating investment in our Oncology/Immunology assets. Baring Private Placement On April 14, 2021, the Company completed the sale of US$100 million of Shares at a price of US$6.10 per Share (equivalent to an ADR price of US$30.50 per ADS) via a private placement to Pachytene Limited, an investment holding company wholly owned by Baring Asia Private Equity Fund VII.
Load more

Recommended publications
  • Current and Future Natural Gas Demand in China and India
    Global Gas/LNG Research Current and Future Natural Gas Demand in China and India By Miranda Wainberg Senior Energy Advisor Michelle Michot Foss, Ph.D. Chief Energy Economist and Program Manager Gürcan Gülen, Ph.D. Senior Energy Economist and Research Scientist Daniel Quijano Economist and Research Associate April 2017 April 2017, BEG/CEE China/India Gas Demand, Page 1 TABLE OF CONTENTS ESSENTIAL ACRONYMNS, UNITS AND CONVERSIONS ................................................................................................... 5 ACKNOWLEDGMENTS .................................................................................................................................................... 6 PREFACE ......................................................................................................................................................................... 7 INTRODUCTION ............................................................................................................................................................. 8 MACROECONOMIC CONTEXT FOR NATURAL GAS IN CHINA AND INDIA ...................................................................... 9 Composition of GDP and Employment Structure ...................................................................................................... 9 GDP Growth and Industrial Structures in China and India ...................................................................................... 11 Industrial overcapacity and debt in China .........................................................................................................
    [Show full text]
  • Occupational Characteristics and Management Measures of Sporadic
    Occupational characteristics and management measures of sporadic COVID-19 outbreaks from June 2020 to January 2021 in China: the importance of tracking down “patient zero” Maohui Feng 1,a, Qiong Ling 2,a, Jun Xiong 3, Anne Manyande 4, Weiguo Xu 5, Boqi Xiang 6,* 1 Department of Gastrointestinal Surgery, Wuhan Peritoneal Cancer Clinical Medical Research Center, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuhan 430071, Hubei, PR China; 2 Department of Anesthesiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong, PR China; 3 Hepatobiliary Surgery Center, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; 4 School of Human and Social Sciences, University of West London, London, United Kingdom； 5 Department of Orthopedics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR China； 6 School of Public Health, University of Rutgers, New Brunswick, NJ 08854, USA. a These authors have contributed equally to this work. *Correspondence: Boqi Xiang, E-mail: [email protected] Abstract There are occupational disparities in the risk of contracting COVID-19. Occupational characteristics and work addresses play key roles in tracking down “patient zero”. The present descriptive analysis for occupational characteristics and management measures of sporadic COVID-19 outbreaks from June to December 2020 in China offers important new information to the international community at this stage of the pandemic. These data suggest that Chinese measures including tracking down “patient zero”, launching mass COVID-19 testing in the SARS-CoV-2-positive areas, designating a new high or medium-risk area, locking down the corresponding community or neighborhood in response to new COVID-19 cases and basing individual methods of protection on science, are effective in reducing transmission of the highly contagious SARS-CoV-2 across China.
    [Show full text]
  • Innovent Biologics (1801
    22 Jul 2021 CMB International Securities | Equity Research | Company Initiation Innovent Biologics (1801 HK) BUY (Initiation) Growing into a global biopharma company Target Price HK$120.91 Up/Downside +43.00% Current Price HK$84.55 Rich innovative drug pipelines. Innovent is a leading integrated biopharma company with comprehensive innovative pipelines including monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), small molecules and CAR- China Healthcare Sector T therapies, covering oncology, autoimmune and metabolic diseases. Besides five marketed products (sintilimab, three biosimilars and pemigatinib), Jill Wu, CFA Innovent has six innovative drugs in pivotal clinical stage, including IBI306 (852) 3900 0842 (PCSK9 antibody), IBI310 (CTLA-4 antibody), IBI376 (PI3Kδ inhibitor), IBI326 [email protected] (BCMA-CART), taletrectinib (ROS1/NTRK inhibitor) and HQP1351 (olverembatinib, third-generation BCR-ABL TKI). In addition, Innovent has Sam Hu, PhD established a comprehensive innovative portfolio covering next-generation (852) 3900 0882 immuno-oncology (I/O) targets, including CD47/SIRPα, TIGT, LAG3, 4-1BB, [email protected] etc. It’s worth noting that Innovent is an early mover in CD47-SIRPα pathway with three assets under development, including clinical-stage IBI188 (a CD47 Jonathan Zhao antibody) and IBI322 (a PD-L1/CD47 bispecific antibody), and preclinical (852) 6359 1614 stage IBI397 (AL008, a SIRPα antibody). [email protected] Tyvyt being an early mover in large indications. After the approval for r/r- cHL in Dec 2018, Tyvyt has been approved by the NMPA for 1L ns-NSCLC, Mkt. Cap. (HK$ mn) 123,312 1L s-NSCLC and 1L HCC in 2021. These three large indications may be Avg.
    [Show full text]
  • A Phase I Study of Pexidartinib, a Colony-Stimulating Factor 1 Receptor Inhibitor, in Asian Patients with Advanced Solid Tumors
    Investigational New Drugs https://doi.org/10.1007/s10637-019-00745-z PHASE I STUDIES A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors Jih-Hsiang Lee1 & Tom Wei-Wu Chen2 & Chih-Hung Hsu2,3 & Yu-Hsin Yen2 & James Chih-Hsin Yang2,3 & Ann-Lii Cheng2,3 & Shun-ichi Sasaki4 & LiYin (Lillian) Chiu5 & Masahiro Sugihara4 & Tomoko Ishizuka4 & Toshihiro Oguma4 & Naoyuki Tajima4 & Chia-Chi Lin2,6 Received: 15 January 2019 /Accepted: 7 February 2019 # The Author(s) 2019 Summary Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase inhibitor, has strong selectivity against colony- stimulating factor 1 receptor. This phase I, nonrandomized, open-label multiple-dose study evaluated pexidartinib safety and efficacy in Asian patients with symptomatic, advanced solid tumors. Materials and Methods Patients received pexidartinib: cohort 1, 600 mg/d; cohort 2, 1000 mg/d for 2 weeks, then 800 mg/d. Primary objectives assessed pexidartinib safety and tolerability, and determined the recommended phase 2 dose; secondary objectives evaluated efficacy and pharmacokinetic profile. Results All11patients(6males,5 females; median age 64, range 23–82; cohort 1 n = 3; cohort 2 n = 8) experienced at least one treatment-emergent adverse event; 5 experienced at least one grade ≥ 3 adverse event, most commonly (18%) for each of the following: increased aspartate aminotransfer- ase, blood alkaline phosphatase, gamma-glutamyl transferase, and anemia. Recommended phase 2 dose was 1000 mg/d for 2 weeks and800mg/dthereafter.Pexidartinibexposure,areaundertheplasmaconcentration-timecurvefromzeroto8h(AUC0-8h), and maximum observed plasma concentration (Cmax) increased on days 1 and 15 with increasing pexidartinib doses, and time at Cmax (Tmax) was consistent throughout all doses.
    [Show full text]
  • Press Release
    Press Release Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201) Collaboration combines Daiichi Sankyo’s scientific and technological excellence with AstraZeneca’s global experience and resources in oncology to accelerate and expand the potential of [fam-] trastuzumab deruxtecan as monotherapy and combination therapy across a spectrum of HER2 expressing cancers AstraZeneca to pay Daiichi Sankyo up to $6.90 billion in total consideration, including $1.35 billion upfront payment and up to an additional $5.55 billion contingent upon achievement of future regulatory and sales milestones as well as other contingencies Companies to share equally development and commercialization costs as well as profits worldwide from [fam-] trastuzumab deruxtecan with Daiichi Sankyo maintaining exclusive rights in Japan Daiichi Sankyo is expected to book sales in U.S., certain countries in Europe, and certain other markets where Daiichi Sankyo has affiliates; AstraZeneca is expected to book sales in all other markets worldwide, including China, Australia, Canada and Russia Tokyo, Munich and Basking Ridge, NJ – (March 28, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s lead antibody drug conjugate (ADC), [fam-] trastuzumab deruxtecan (DS-8201), currently in pivotal development for multiple HER2 expressing cancers including breast and gastric cancer, and additional development in non-small cell lung and colorectal cancer. Daiichi Sankyo and AstraZeneca will jointly develop and commercialize [fam-] trastuzumab deruxtecan as a monotherapy or a combination therapy worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights.
    [Show full text]
  • Daiichi Sankyo Group Value Report 2019
    External Evaluations (as of June 30,2019) ™ Daiichi Sankyo Group Value Report 2019 Value Daiichi Sankyo Group MSCI Japan Empowering Women Select Index THE INCLUSION OF DAIICHI SANKYO CO.,LTD. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF DAIICHI SANKYO CO.,LTD. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADE- MARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES. “Eruboshi” Certification Mark “Kurumin” Certification Mark Logo given to Certified Health and Productivity Management Organization (White500) This report uses FSC® certified paper, which indicates that the paper used to print this Paper report was produced from properly managed forests. 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan This report was printed using 100% Inks biodegradable printing inks from vegetable Corporate Communications Department oil. Daiichi Sankyo Group Tel: +81-3-6225-1126 CSR Department The waterless printing method used for this Value Report 2019 Tel: +81-3-6225-1067 Printing report minimized the use and release of harmful liquid wastes. https://www.daiichisankyo.com/ Printed in Japan 005_7045687911909.indd 1 2019/09/27 18:22:19 Introduction Our Mission The Core Values and Commitments serve as the criteria for business activities and In addition, we have established the DAIICHI SANKYO Group Corporate Conduct Charter . decision-making used by executive officers and employees in working to fulfill Our Mission . This charter calls on us to fulfill our social responsibilities by acting with the highest ethical Our Corporate Slogan succinctly explains the spirit of Our Mission, Core Values and standards and a good social conscience appropriate for a company engaged in business Commitments.
    [Show full text]
  • The Tumor Microenvironment and Overcoming Immune Escape Arsen Osipov1, May Tun Saung1, Lei Zheng1 and Adrian G
    Osipov et al. Journal for ImmunoTherapy of Cancer (2019) 7:224 https://doi.org/10.1186/s40425-019-0667-0 REVIEW Open Access Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape Arsen Osipov1, May Tun Saung1, Lei Zheng1 and Adrian G. Murphy1,2* Abstract Immunotherapy has led to a paradigm shift in the treatment of many advanced malignancies. Despite the success in treatment of tumors like non-small cell lung cancer (NSCLC) and melanoma, checkpoint inhibition-based immunotherapy has limitations. Many tumors, such as pancreatic cancer, are less responsive to checkpoint inhibitors, where patients tend to have a limited duration of benefit and where clinical responses are more robust in patients who are positive for predictive biomarkers. One of the critical factors that influence the efficacy of immunotherapy is the tumor microenvironment (TME), which contains a heterogeneous composition of immunosuppressive cells. Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) alter the immune landscape of the TME and serve as facilitators of tumor proliferation, metastatic growth and immunotherapy resistance. Small molecule inhibitors that target these components of the TME have been developed. This special issue review focuses on two promising classes of immunomodulatory small molecule inhibitors: colony stimulating factor-1 receptor (CSF-1R) and focal adhesion kinase (FAK). Small molecule inhibitors of CSF-1R reprogram the TME and TAMs, and lead to enhanced T-cell-mediated tumor eradication. FAK small molecule inhibitors decrease the infiltration MDSCs, TAMs and regulatory T-cells. Additionally, FAK inhibitors are implicated as modulators of stromal density and cancer stem cells, leading to a TME more conducive to an anti-tumor immune response.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Phase Ib Study of the Combination of Pexidartinib (PLX3397), a CSF-1R Inhibitor, and Paclitaxel in Patients with Advanced Solid
    TAM0010.1177/1758835919854238Therapeutic Advances in Medical OncologyR Wesolowski, N Sharma 854238research-article20192019 Therapeutic Advances in Medical Oncology Original Research Ther Adv Med Oncol Phase Ib study of the combination of 2019, Vol. 11: 1 –13 DOI:https://doi.org/10.1177/1758835919854238 10.1177/ pexidartinib (PLX3397), a CSF-1R inhibitor, 1758835919854238https://doi.org/10.1177/1758835919854238 © The Author(s), 2019. Article reuse guidelines: and paclitaxel in patients with advanced sagepub.com/journals- solid tumors permissions Robert Wesolowski, Neelesh Sharma, Laura Reebel, Mary Beth Rodal, Alexandra Peck, Brian L. West, Adhirai Marimuthu, Paul Severson, David A. Karlin, Afshin Dowlati, Mai H. Le, Lisa M. Coussens and Hope S. Rugo Abstract Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors. Patients and Methods: In part 1 of this phase Ib study, 24 patients with advanced solid tumors received escalating doses of pexidartinib with weekly paclitaxel (80 mg/m2). Pexidartinib was administered at 600 mg/day in cohort 1. For subsequent cohorts, the dose was increased by ⩽50% using a standard 3+3 design. In part 2, 30 patients with metastatic solid tumors were enrolled to examine safety, tolerability and efficacy of the RP2D. Pharmacokinetics and biomarkers were also assessed. Results: A total of 51 patients reported ≥1 adverse event(s) (AEs) that were at least possibly related to either study drug. Grade 3–4 AEs, including anemia (26%), neutropenia (22%), lymphopenia (19%), fatigue (15%), and hypertension (11%), were Correspondence to: Robert Wesolowski recorded in 38 patients (70%).
    [Show full text]
  • Systematic Review: Targeting HER2 in Bladder Cancer
    Bladder Cancer 5 (2019) 1–12 1 DOI 10.3233/BLC-180196 IOS Press Systematic Review Systematic Review: Targeting HER2 in Bladder Cancer Vadim S. Koshkina, Peter O’Donnellb,EvanY.Yuc and Petros Grivasd,∗ aDepartment of Medicine, Division of Hematology and Oncology, University of California San Francisco, CA, USA bDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA cDepartment of Medicine, Division of Oncology, Clinical Research Director, Fred Hutchinson Cancer Research Center, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA dDepartment of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA Received 23 August 2018 Accepted 22 November 2018 Abstract. Background: HER2 (ErbB2) is a receptor of the Human Epidermal Growth Factor Receptor (HER) family whose role in oncogenesis of numerous malignancies is well described. Drugs targeting HER2 are currently approved in breast and gastroesophageal cancers while pan-HER targeting agents are being evaluated in multiple malignancies. HER2 genomic alterations are commonly described in urothelial cancer and multiple trials have assessed the efficacy of anti-HER2 agents in both muscle-invasive and metastatic urothelial carcinoma. Objective: To review prospective clinical trials of therapeutic agents with HER2–targeting activity in patients with bladder cancer. Methods: A systematic search of PubMed, ASCO abstracts and Clinicaltrials.gov was performed to identify studies of HER2–targeting agents in bladder cancer. Reported results from prospective trials were reviewed and summarized. Results: Eleven prospective clinical trials with reported results were identified that investigated activity of trastuzumab, lapatinib, neratinib, afatinib, or autologous cellular immunotherapy, (DN24–02), in various bladder cancer treatment settings.
    [Show full text]
  • Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer
    Bladder Cancer 5 (2019) 87–102 87 DOI 10.3233/BLC-180205 IOS Press Review Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer Tony Ibrahima, Marco Gizzib, Ratislav Bahledac and Yohann Loriota,d,∗ aD´epartement de M´edecine Oncologique, Gustave Roussy, Universit´e Paris-Sud, Universit´e Paris-Saclay, Villejuif, France bDepartment of Medical Oncology. Grand Hˆopital de Charleroi, Charleroi, Belgium cDrug Development Department (DITEP), Gustave Roussy, Villejuif France dInserm 981, Universit´e Paris-Sud, Universit´e Paris Saclay, Villejuif, France Received: 29 November 2018 Accepted: 4 March 2019 Abstract. The fibroblast growth factor receptor 3 (FGFR3) plays critical roles in driving oncogenesis of a subset of patients with urothelial carcinomas (UC). Growing evidence from preclinical studies suggests that FGFR3 inhibition can reduce proliferation and survival in vitro and in vivo models of FGFR3-altered UC. Early clinical trials investigating selective FGFR3 inhibitor have reported preliminary signs of antitumor activity in advanced UC patients with selected FGFR3 mutations or fusions. Currently, phase 3 trials with erdafitinib and rogaratinib are enrolling patients with known FGFR3 alterations. Future combinations with targeted therapies or immune checkpoint inhibitors may increase the efficacy of selective FGFR3 inhibitors. Herein, we discuss current clinical development of FGFR3 inhibitors as well as unsolved questions with regards to patient selection, management of toxicities and mechanisms of resistance to selective FGFR3 inhibitors. Keywords: Urothelial cancer, bladder cancer, fibroblast growth factor 3, tyrosine kinase INTRODUCTION the treated patients [1–11]. Innovative strategies aim- ing to improve metastatic UC treatment efficacy have Metastatic urothelial carcinoma (UC) is frequent learned from targeted therapies in solid tumors such and has a poor prognosis.
    [Show full text]
  • New ADC Shrinks HER2-Positive Tumors
    Published OnlineFirst August 2, 2019; DOI: 10.1158/2159-8290.CD-NB2019-089 NEWS IN BRIEF he says, “I can’t cancer, and 17 had HER2-low HR- fathom that cost.” negative breast cancer. The remaining Cytoplasm –Elie Dolgin n 47 patients had gastric, urothelial, or endometrial tumors. Eye-related side effects were again New ADC prevalent: 71% of patients were Shrinks affected by problems such as conjunc- tivitis, keratitis, and dry eye. These Nuclear pore HER2- adverse effects have been seen with complex Positive other ADCs—although they haven’t Tumors been described with T-DM1—but the mechanism remains unclear, says A novel co-author Philippe Aftimos, MD, of Nucleus antibody–drug the Jules Bordet Institute and the Free conjugate (ADC) University of Brussels in Belgium. Tumor suppressor protein Selective inhibitor of triggers responses nuclear export inhibitor The ADC produced partial + eiF4E-bound mRNA in patients with Regulatory factor XPO1 responses in 33% of the patients with HER2-expressing HER2-positive metastatic breast breast cancer Selinexor is a selective inhibitor of nuclear export. By blocking XPO1, it cancer; 28% with HER2-low, HR- prevents molecular cargo from moving through the nuclear pore complex, and other solid positive metastatic breast cancer; and causing cell-cycle arrest, apoptosis, and other antitumor activity. (Courtesy tumors, a phase I 40% with HER2-low, HR-negative of Karyopharm Therapeutics; modified with permission.) clinical trial metastatic breast cancer. The median indicates (Lancet progression-free survival for these Oncol 2019;20:1124–35). The drug commonly experienced side effects three groups was 7.6 months, such as thrombocytopenia, hypona- could become a new treatment for 4.1 months, and 4.9 months, respec- tremia, anemia, and nausea.
    [Show full text]